CT Biotech is proud to announce that it has received the Tier 1 Award at IFC 2026 – Incheon Foreign Start-up Challenge in Korea.
This recognition marks an important milestone in CT Biotech’s international growth journey and reflects the global potential of our biotechnology-based solutions in probiotics, postbiotics, microbial formulations, and functional product development.
The Incheon Foreign Start-up Challenge supports promising international start-ups aiming to expand their business and innovation activities in Korea. Being selected for the Tier 1 Award strengthens CT Biotech’s position within the Korean start-up ecosystem and supports our ongoing efforts to build stronger business, R&D, and manufacturing partnerships between Türkiye, Korea, and global markets.
At CT Biotech, we develop science-based, scalable, and market-oriented biotechnology solutions for multiple industries, including hygiene, personal care, pet care, textiles, indoor air quality, agriculture, and functional ingredients. Our work focuses on transforming microbial science into applicable products, private-label solutions, and B2B technologies.
Winning the IFC 2026 Tier 1 Award is not only an achievement for our company, but also a meaningful validation of our vision: to build a globally connected biotechnology company that brings probiotic and postbiotic innovation into everyday life.
We would like to thank the IFC 2026 program, the Incheon start-up ecosystem, our partners, mentors, and everyone who has supported CT Biotech’s international journey.
This award motivates us to continue expanding our activities in Korea and to develop new collaborations in biotechnology, microbial ingredients, functional formulations, and international business development.
